Dr. Robert Wesolowski, MD

Dr. Wesolowski practices at OSU Internal Medicine in Columbus, Ohio.

Dr. Wesolowski's NPI, 1821264623, was assigned on May 1, 2008. Dr. Wesolowski holds Ohio license 35.095721.

Dr. Wesolowski's primary practice is OSU Internal Medicine, at 1145 Olentangy River Rd, Columbus, OH 43212 in Franklin County. The practice phone is (614) 293-2229.

Dr. Wesolowski's primary practice is OSU Internal Medicine in Columbus, Ohio. Dr. Wesolowski is also affiliated with Ohio State University Hospital. The medical group on file is Ohio State University Physicians. Dmand AI also links Dr. Wesolowski to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wesolowski practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Wesolowski's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Wesolowski is licensed in Ohio.

CMS data shows 306 Medicare services from Dr. Wesolowski across 4 procedure codes in 2024, for 142 Medicare patients. Medicare paid $20,444 for them. Every service was in an office.

CMS counts 142 Medicare patients who saw Dr. Wesolowski in 2024. The largest group is 65 to 74, with 84 patients. 75% of them have cancer, and 74% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wesolowski's median patient age at 66, with 94% women.

In 2024, Dr. Wesolowski wrote 398 Medicare Part D claims for 111 patients. 72% of them were for generic drugs. CMS names the drug for 250 of them, across 9 drugs with 11 or more claims each, at $1,252,429 in total drug cost. In 2023, CMS named 244 claims across 10 drugs.

Dr. Wesolowski accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 122 papers to Dr. Wesolowski, published from 2011 to 2025. 2020 was the busiest year, with 16. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Receptor, ErbB-2. Dr. Wesolowski has published most often in Clin Cancer Res. Dr. Wesolowski's most frequent co-authors are Sagar D. Sardesai, MD, Daniel G. Stover, MD and Mathew Amprayil Cherian, MD.

Dmand AI links Dr. Wesolowski to 12 clinical trials, 5 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Neoplasm Metastasis. Agenus Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Wesolowski that name 3 trials.

CMS Open Payments shows 36 general payments to Dr. Wesolowski from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. Pfizer Inc. paid the most, $14,218. It also lists 7 research payments totaling $263,640 from 2016 to 2020, naming 3 clinical trials.